5 chatbots ranked by ‘credibility,’ according to patients

Although healthcare providers are increasingly considering telemedicine options such as chatbots, the jury is still out on whether patients trust these new modes of care delivery, according to a report from customer experience company UserTesting.

Advertisement

To assess patient attitudes toward the use of chatbots in healthcare, UserTesting polled 500 consumers about their experiences using five popular healthcare chatbot apps. UserTesting then applied a scoring algorithm to quantify the user experience.

How the five apps ranked on credibility, according to the report:

  1. Ada (82.7 percent)
  2. Mediktoy (69.4 percent)
  3. Your.MD (47.1 percent)
  4. HealthTap (46 percent)
  5. Symptomate (41.4 percent)

Most respondents (73 percent) said the chatbots were helpful, compared with 12 percent said they were not. Fifteen percent of respondents said they were neutral.

To access the complete report, click here.

More articles on patient engagement:

Boston Children’s Hospital, Medumo join forces to support patient care journeys
Mass General physicians develop pain management app for cancer patients
Val Verde Regional Medical Center implements patient education solution

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

New language access rules are reshaping patient experience: Lessons from Denver Health and UnityPoint Health

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Dipak Patel, GLOBOTyler Gegen, MBA, FACHE, CPXP, UnityPoint HealthMaria Pamboukis, M.D. CPXP., Denver Health

Advertisement

Next Up in Patient Experience

Advertisement

Comments are closed.